It's hard to call it a bad thing when Wall Street likes a stock, but rising expectations can create problems of their own. St. Jude Medical (NYSE: STJ )
seems to have done a good job of selling the Street on the idea that
it has turned over a new leaf and that accelerating growth is around the
corner.
Sell-side price targets are about 20% higher now than at the
beginning of 2014, and the buy/hold/sell recommendation breakdown has
moved from 11-10-3 to 14-8-2 over the past three months, though the EPS
targets for 2014 and 2015 have hardly budged. That optimism may well
explain why St. Jude's "good enough" first quarter wasn't quite good
enough for investors.
Read the complete article here:
St. Jude Medical Inc.: In-Line Is Just Not Good Enough
No comments:
Post a Comment